ATS’s regulated automation moat and Life Sciences backlog offer recovery potential, but a 2.9x leverage load and restructuring execution make the turnaround contingent on cost savings and demand normalization.
Overview
ATS Corporation designs, builds, and services custom automation and assembly systems for global manufacturers, with roughly 7,000 employees, more than 65 manufacturing facilities, and over 85 offices. It serves regulated and uptime-critical customers across Life Sciences, Food & Beverage, Energy, Industrial & Consumer, and Transportation. Revenue is diversified across construction contracts (about 52%), products (22%), and services and digital (26%); recurring revenue is estimated at 25%–35%. The strategic advantage is a global execution network, proprietary technology, and high switching costs in pharmaceutical lines integrated with regulatory filings. Q1 FY2027 was weak: adjusted revenue fell 5.2% to CAD 698.3 million, adjusted operating margin contracted to 9.8%, and adjusted EPS declined to CAD 0.35. Revenue and EPS also missed USD consensus estimates, prompting a 21.15% one-session share decline. Management reiterated modest FY2027 organic growth, contingent on stronger second-half bookings, and launched an 18-month program targeting CAD 60–70 million in annualized savings. **The long-term moat and regulated-market backlog remain intact, but near-term execution and leverage are significant constraints.** At about 18.3x forward P/E and 11.5x TTM EV/EBITDA, the shares are below five-year averages of about 22x and 14x, respectively. **The central catalyst is converting backlog and cost savings into margin recovery toward 15%.**